Last reviewed · How we verify
NCT06796283
Research on AIS Recurrence Risk Prediction Model Using XGBoost Combined With Convolutional Neural Network Algorithm
trial in Ischemic Stroke in 2,628 participants. Completed in 31 December 2024.
4 March 2023
Quick facts
| Lead sponsor | Second Affiliated Hospital of Nanchang University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,628 |
| Start date | 26 April 2021 |
| Primary completion | 4 March 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Second Affiliated Hospital of Nanchang University
Who can join
Adults 18 to 85, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this observational study is to construct a recurrence risk prediction model for ischemic stroke within 1, 3, 6, and 12 months using XGBoost combined with Convolutional Neural Network (CNN) algorithm. Method: Follow up was conducted on the study subjects at 1, 3, 6, and 12 months after discharge. Follow up primary outcome: Whether the study subjects experienced recurrent stroke events. Secondary outcome: Improved Rinkin score. Collect information on research subjects: It includes demographic data, physical examination, medical history, imaging images, medication use, scale scores, CYP2C19 genotype test results, laboratory tests, and other complex multidimensional data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06796283
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Second Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT07346794 — The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease · NA · not yet recruiting
- NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
- NCT07401784 — Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of I · NA · not yet recruiting
- NCT07290699 — Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period · Phase 4 · not yet recruiting
- NCT07295444 — A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mil · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06796283 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Nanchang University
- Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06796283.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing